Poor Ovarian Response Clinical Trial
Official title:
The Influence of Concomitant Co Enzyme Q10 Use on Pregnancy Outcome in Intrauterine Insemination
As women age the ovarian response and pregnancy rate are reduced while the rate of chromosomal abnormalities in the embryos is increased. Oocyte maturation, accurate chromosomal segregation as well as early embryo development and implantation are dependent on the supply of large amounts of energy, which unlike other cells can only arise from the mitochondria. With age the mitochondria becomes less efficient due to damage to its unique DNA, resulting in decreased energy production. The proposed study will examine the effect of the combination of a dietary supplement, Co enzyme Q10 on pregnancy rate and response of the ovaries to a medication that stimulates follicle growth. The investigators hypothesize that the improved energetic state of the oocyte would result in a more accurate chromosomal separation, increased embryo quality and pregnancy rate.
The study will be organized on an outpatient basis at the Toronto Centre for Advanced
Reproductive Technology (TCART) and at the Lifequest Centre for Reproductive Medicine. The
study will involve 100 women aged 38-43 years.
In the first cycle, study participants will be randomly assigned to either placebo or COQ10
capsules, (AOR - Advanced Orthomolecular Research Inc. 19 St NE Calgary, Alberta, NHPD
registration codes 135307 and 113519, respectively). Study participants will take 600 mg of
CoQ10 orally or identical placebo capsules for up to 5 cycles if pregnancy does not occur.
All subjects will commence controlled ovarian stimulation (COH) using highly purified human
menopausal gonadotropins (Menopur; Ferring Inc., North York,Ontario Canada). The starting
dosage of Menopur will range from 75IU to 250 IU daily S.C. will be determined by the
physician and will begin on the third day of menses, and will continue until the day prior
to human chorionic gonadotropin (hCG) administration. The dosage will not be changed and
must be maintained for the duration of the study. Menopur will continue daily until
follicular development is considered adequate. (at least 1 follicle is >17 mm, and the E2
level is acceptable for the number of follicles present). The patient will receive an
injection of hCG 250 mcg (Ovidrel, EMD Serono,Oakville, Ontario, Canada ), SC for the final
stage of follicular maturation. Insemination will be by intrauterine insemination (IUI).
Luteal support will consist of progesterone suppositiories 200mg (Kingsway Pharmacy,Toronto,
Ontario Canada) vaginally per day starting on the day of IUI and will continue for 2 weeks
until the serum beta hCG result. At the end of each cycle serum beta hCG will be drawn and
if women are pregnant CoQ10/ placebo will be discontinued. If pregnant, luteal support will
continue until 10 weeks gestation. If the patient is not pregnant she will have a cycle off
COH but may attempt to conceive naturally. In the third cycle, COH using the same dose of
Menopur as in the first cycle will be performed with IUI as in cycle one. If not pregnant,
another cycle off treatment will be followed by the fifth cycle in which COH and IUI is
performed..
The study endpoints will be:
1. Primary outcome measure will be pregnancy rate.
2. Secondary outcome measures will include:
- Peak estradiol level
- The number of follicles > 14 mm on day of hCG
- Number of days of stimulation / units of Menopur needed
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03433768 -
Androgen Receptor mRNA Expression is Positively Associated With Live Birth in Women Undergoing IVF Independently of the Type of Ovarian Response
|
N/A | |
Recruiting |
NCT05601193 -
Ovarian PRP Injection in Women With POR
|
N/A | |
Suspended |
NCT03021915 -
Single Center, Prospective Controlled Pilot Study of the OvaPrime Procedure
|
N/A | |
Completed |
NCT04013984 -
Acupuncture for Treatment of Patients With Poor Ovarian Response
|
N/A | |
Completed |
NCT03447184 -
Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study
|
||
Completed |
NCT01816321 -
Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial
|
Phase 3 | |
Recruiting |
NCT04310293 -
Novel Therapy for Poor Responders Management
|
N/A | |
Completed |
NCT05703308 -
Menstrual Blood Stem Cells in Poor Ovarian Responders
|
Phase 3 | |
Not yet recruiting |
NCT06089395 -
The Effect of Jiajian Guishen Granules on the Modulation of Ovarian Function in Patients With Poor Ovarian Response(POR)
|
Early Phase 1 | |
Completed |
NCT01732094 -
Corifollitropin Alfa Followed by hpHMG in a Long GnRH Agonist Protocol for the Treatment of Poor Ovarian Responders
|
Phase 2 | |
Completed |
NCT01732068 -
Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol
|
Phase 2 | |
Recruiting |
NCT04717752 -
A Randomized Controlled Study of Different Trigger Modes of Antagonist Regimen in Patients With Low Ovarian Reserve
|
N/A | |
Recruiting |
NCT04024722 -
Improving in Vitro Fertilization in Women With Poor Ovarian Response
|
N/A | |
Completed |
NCT03994614 -
the Effect of Transcutaneous Electrical Acupoint Stimulation on the Quality of Oocyte on Poor Ovarian Response(POR)
|
N/A | |
Recruiting |
NCT03830697 -
A Trial Study on Acupuncture Treatment of Poor Ovarian Response
|
N/A | |
Recruiting |
NCT02801591 -
Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET
|
N/A | |
Recruiting |
NCT04273256 -
Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT02993588 -
Impact of Melatonin on IVF/ICSI Outcomes in Prospective Poor Responders
|
Phase 2/Phase 3 | |
Terminated |
NCT02418572 -
Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial
|
Phase 3 |